Endocrine Disorders for the USMLE, Step One:

Multiple Endocrine Neoplasia Type 1 (MEN-1 Syndrome)

Howard J. Sachs, MD www.12DaysinMarch.com Endocrine Disorders for the USMLE, Step One:

Multiple Endocrine Neoplasia Type 1 View MEN2 Syndromes BEFORE (MEN-1 Syndrome) this video

Howard J. Sachs, MD www.12DaysinMarch.com MEN-1 Syndrome

Pituitary Parathyroid MEN-1 Syndrome

Pituitary Parathyroid Pancreas

3-P’s MEN-1 Syndrome

Pituitary Parathyroid Pancreas

3-P’s MEN-1 Syndrome

Before proceeding, we need to change the name into something more memorable and informative.

Once we move from MEN-1 and the 3-P’s, the rest is a breeze.

Pituitary ParathyroidReally. Pancreas

3-P’s MEN-1 Syndrome

Parathyroid Pancreas Pituitary

~100% ~60% ~20% MEN-1 Syndrome

Parathyroid Pancreas Pituitary

~100% ~60% ~20%

Multiple (ZE) MEN-1 Syndrome

Pituitary Pancreas Parathyroid

~20% ~60% ~100%

Prolactinoma Gastrinoma (ZE)  Ca+2 MEN-1 Syndrome

Pituitary Pancreas Parathyroid

~20% ~60% ~100%

Prolactinoma Gastrinoma (ZE)  Ca+2

Pro-ZE-Ca Syndrome MEN 1: Pro-ZE-Ca Syndrome

Pituitary Pancreas Parathyroid

~20% ~60% ~100%

Prolactinoma Gastrinoma (ZE) Multiple Adenomas

Mass Effect Multiple/Atypical  Ca+2 Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome

What are the take homes?

Background: A. High penetrance B. Initial presention in majority of MEN C. Compared with sporadic: • PituitaryMultiple adenomas and earlyPancreas age Parathyroid

~20% Presentation: ~60% ~100% D. SameProlactinoma as any other patientGastrinoma with hyperPTH (ZE) Multiple Adenomas •  Ca,  PTH,  PO4- • MassStones, Effect Constipation Multiple/Atypical  Ca+2 Hormonal• X- Dysfunctionray: subperiosteal bone Ulcersresorption MEN 1: Pro-ZE-Ca Syndrome

What are the take homes?

Background: A. High penetrance B. Initial presention in majority of MEN C. Compared with sporadic: • PituitaryMultipleOn USMLE, adenomas any patient and early diagnosedPancreas age or presentingParathyroid with HyperPTH, you need be HyperVigilent for an ~20% MENPresentation Syndrome: (Type~60% 1 or 2a) ~100% D. SameProlactinoma as any other patientGastrinoma with hyperPTH (ZE) Multiple Adenomas •  Ca,  PTH,  PO4- • MassStones, Effect Constipation Multiple/Atypical  Ca+2 Hormonal• X- Dysfunctionray: subperiosteal bone Ulcersresorption MEN 1: Pro-ZE-Ca Syndrome What are the take homes?

Background (Pancreatic Endocrine Tumors): A. Gastrinoma most common • May present in duodenal location B. , VIPoma, • Hypoglycemia, WDHA, NME (bronze skin) C. (bronchial, thymus) Pancreas Pituitary Pancreas

Presentation: ~60% ~20% ~60% D. Multiple or Atypical Ulcers Gastrinoma (ZE) • ProlactinomaDuodenal beyond D1 Gastrinoma (ZE) • Epigastric pain despite rx Multiple/Atypical E. DiarrheaMass Effect (inactivates lipase/acidicMultiple/Atypical lumen) Ulcers Hormonal Dysfunction Ulcers

MEN 1: Pro-ZE-Ca Syndrome

What are the take homes?

Diagnostics (Gastrinoma):

1. High gastric basal acid secretion Pancreas 2.  GastrinPituitary Level Pancreas 3. Secretin Stimulation Test ~60% • Rise~20% in Gastrin Level ~60%

Gastrinoma (ZE) Prolactinoma Gastrinoma (ZE) Multiple/Atypical Mass Effect Multiple/Atypical Ulcers Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome

WhatBe on are the the lookout take homes? with any question that includes Gastrinoma , VIPoma, or Insulinoma. Diagnostics (Gastrinoma): If they include  Ca+2, you have two components 1. High gastric basal acid secretionof MEN-1… Pancreas 2.  GastrinPituitary Level Pancreas 3. Secretin Stimulation…they will Test most assuredly come after you on the ~60% • Rise~20% in Gastrin Level third component…~60%

Gastrinoma (ZE) Prolactinoma Gastrinomathe Pituitary (ZE) Multiple/Atypical Mass Effect Multiple/Atypical Ulcers Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome

What are the take homes?

Background: 1. Adenomas of follow same pattern as in non-MEN syndromes • > Growth > Null Pituitary • HormonePancreas product versus MassParathyroid Effect

~20% ~60% ~100% Presentation: Prolactinoma 1. PituitaryGastrinoma mass (ZE) lesion: HA, visualMultiple field Adenomas cut 2. Prolactinoma: hypogonadotropic Mass Effect • Male:Multiple/Atypical  libido/ ED  Ca+2 Hormonal Dysfunction Ulcers • Female:  menses, MEN 1: Pro-ZE-Ca Syndrome

What are the take homes?

Diagnostics: 1.  Prolactin level 2. Men:  LH, Pituitary 3. ImagingPancreas for mass effect orParathyroid  PRL

~20% ~60% Note: ~100% Prolactinoma FrequencyGastrinoma (ZE) of pituitary Multiplelesion in Adenomas MEN-1 depends on how hard you look Mass Effect Multiple/Atypical(20% clinical, 60% by MRI screen) Ca+2 Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome

What are the take homes?

Interestingly, I’ve mentioned you should Diagnosticsbe hypervigilant: looking for MEN1 in patients with1. hyperPTH Prolactin and/or level pancreatic masses or neuroendocrine tumors.  2. Men: LH, testosterone Pituitary On the other hand,3. questionsImagingPancreas involving for mass pituitary effect adenomas orParathyroid  PRL are usually focused on the and secretions. ~20% ~60% Note: ~100% Prolactinoma FrequencyGastrinoma (ZE) of pituitary Multiplelesion in Adenomas MEN-1 depends on how hard you look Mass Effect Multiple/Atypical(20% clinical, 60% by MRI screen) Ca+2 Hormonal Dysfunction Ulcers MEN-1 Syndrome

• Reviewed major components – Endocrinopathy (PTH, Pancreas, Pituitary) – Derm Manifestations

Angiofibroma (90%) Collagenoma Lipoma MEN-1 Syndrome Lip/Tongue Neuromas seen in MEN2b • Reviewed major components – Endocrinopathy (PTH, Pancreas, Pituitary) – Derm Manifestations

Angiofibroma (90%) Collagenoma Lipoma MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%;  Ca+2) HyperPTH Marfanoid, Neuromas

The most difficult part of an MEN Syndrome is knowing you are in one… Autosomal Dominant

MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%;  Ca+2) HyperPTH Marfanoid, Neuromas Autosomal Dominant

MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%;  Ca+2) HyperPTH Marfanoid, Neuromas Gain of function Loss of Suppressor

MEN1 RET Mutation Mutation

MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%;  Ca+2) HyperPTH Marfanoid, Neuromas Gain of function Loss of Suppressor

MEN1 RET Mutation Mutation

MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%;  Ca+2) HyperPTH Marfanoid, Neuromas Autosomal Dominant

MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%;  Ca+2) HyperPTH Marfanoid, Neuromas Endocrine Disorders for the USMLE, Step One:

Multiple Endocrine Neoplasia Type 1 (Pro-ZE-Ca or MEN-1 Syndrome)

Pro-ZE-Ca

Howard J. Sachs, MD Email: [email protected]